Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Financing Activities (2016 - 2018)

Historic Cash from Financing Activities for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2018 value amounting to $16.3 million.

  • Soleno Therapeutics' Cash from Financing Activities rose 1504.59% to $16.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $17.8 million, marking a year-over-year decrease of 2624.33%. This contributed to the annual value of $213.0 million for FY2024, which is 1833.47% up from last year.
  • As of Q4 2018, Soleno Therapeutics' Cash from Financing Activities stood at $16.3 million, which was up 1504.59% from $700000.0 recorded in Q3 2018.
  • Soleno Therapeutics' Cash from Financing Activities' 5-year high stood at $16.3 million during Q4 2018, with a 5-year trough of $133.0 in Q4 2016.
  • Over the past 5 years, Soleno Therapeutics' median Cash from Financing Activities value was $2.3 million (recorded in 2015), while the average stood at $4.5 million.
  • Per our database at Business Quant, Soleno Therapeutics' Cash from Financing Activities crashed by 9999.68% in 2016 and then soared by 1065403533.83% in 2017.
  • Over the past 5 years, Soleno Therapeutics' Cash from Financing Activities (Quarter) stood at $9.5 million in 2014, then crashed by 55.86% to $4.2 million in 2015, then crashed by 100.0% to $133.0 in 2016, then soared by 10654035.34% to $14.2 million in 2017, then increased by 15.05% to $16.3 million in 2018.
  • Its last three reported values are $16.3 million in Q4 2018, $700000.0 for Q3 2018, and $537000.0 during Q2 2018.